Brief: Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab
17/11/2025 12:19
Nov 17 (Reuters) - Merus NV 2GH.F: MERUS AND HALOZYME ENTER GLOBAL COLLABORATION AND LICENSE AGREEMENT TO DEVELOP SUBCUTANEOUS FORMULATION OF PETOSEMTAMAB MERUS NV - TO MAKE UPFRONT AND MILESTONE PAYMENTS TO HALOZYME MERUS NV - LICENSES HALOZYME'S ENHANZE FOR PETOSEMTAMAB MERUS NV: HALOZYME WILL ALSO BE ENTITLED TO UP TO LOW-MID SINGLE DIGIT ROYALTIES ON NET SALES OF PETOSEMTAMAB Source text: nPn8JHt7Ja Further company coverage: 2GH.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Halozyme Therapeutics
See all newsUS RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Halozyme wins court order to block Merck's injected Keytruda in select European markets (updated)
US STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
Halozyme wins court order to block Merck's injected Keytruda in select European markets